The effects of glucagon-like peptide-1 on the beta cell

Keyphrases

• A1 Receptor 22%
• B Cells 100%
• Cell Sensitivity 11%
• Clinical Significance 11%
• Dipeptidyl peptidase-4 (DPP-4) 22%
• Exenatide 33%
• First-phase Insulin Secretion 11%
• Glucagon-like 100%
• Glucose-stimulated Insulin Secretion 11%
• Homeostasis Model Assessment 11%
• Incretin Hormones 11%
• Insulin 11%
• Insulin Resistance 11%
• Insulinotropic Effects 11%
• Liraglutide 33%
• Main Class 11%
• Progressive Disease 11%
• Proinsulin 11%
• Receptor Agonist 22%
• Second Phase Insulin Secretion 11%
• Type 2 Diabetes Mellitus (T2DM) 22%
• Type 2 Diabetes Prevention 22%
• Type 2 Diabetic Patients 11%
• β-cell Apoptosis 11%
• β-cell Function 22%
• β-cell Mass 11%
• β-cell Neogenesis 11%
• β-cell Proliferation 11%

Medicine and Dentistry

• Beta Cell 100%
• Cell Function 20%
• Cell Proliferation 10%
• Clinical Study 10%
• Dipeptidyl Peptidase IV 10%
• Dipeptidyl Peptidase-4 Inhibitor 10%
• Exenatide 30%
• Glucagon Like Peptide 1 100%
• Glucagon-Like Peptide-1 Agonist 20%
• Homeostatic Model Assessment 10%
• Incretin 10%
• Insulin Release 20%
• Insulin Resistance 10%
• Liraglutide 30%
• Maturity Onset Diabetes of the Young 40%
• Patient with Type 2 Diabetes 10%
• Programmed Cell Death 10%
• Progressive Disease 10%
• Proinsulin 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Clinical Study 14%
• Dipeptidyl Peptidase IV 14%
• Dipeptidyl Peptidase IV Inhibitor 14%
• Disease 14%
• Exendin 4 42%
• Glucagon Like Peptide 1 Receptor Agonist 28%
• Glucagon-Like Peptide-1 100%
• Incretin 14%
• Insulin Resistance 14%
• Liraglutide 42%
• Non Insulin Dependent Diabetes Mellitus 71%
• Preclinical Study 14%
• Proinsulin 14%